An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program with More than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab
April Armstrong, Noah Agada, Wen Xu, Gaia Gallo
Abstract not available.
Disclosures: Study sponsored by Eli Lilly & Company.
Copyright 2018 SKIN
Abstract - 174 Poster PDF - 35
- There are currently no refbacks.